Biogen Message Board - Msg: 336351

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 177.82

+1.0%

Jan 2 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (38)	10/8/1996 11:46:00 AM
From: Rick Lundberg	of 1686

Harold, Saw your comment about the PNU/Genotropin license. $30m upfront will be booked in Q3. Ongoing royalties slightly above $10m (more as Genotropin sales increase). As for the EPS effect, remember that we will have COGS on the $$ (undisclosed royalty to Harvard) and that the $$$ will be taxed at our US tax rate of 43%. In Q3 we will also recognize ~$23m of R&D tax credits. We WILL be at an operating profit ex-PNU and tax credits. Suffice to say, we'll have a nice quarter. We're reporting tomorrow (Wed Oct 9) after the close. I'll post the transcript when it is available on Thurs. Rick Lundberg Biogen Investor Relations

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next